Thor Medical ASA (FRA:8NN) Asset Turnover: 0.00 (As of Dec. 2025)


FRA:8NN Thor Medical ASA FRA:8NN
26 GF Score
Price €0.37
! 2 Warning Signs
View Full Analysis

What is Thor Medical ASA Asset Turnover?

Thor Medical ASA FRA:8NN -1.60% 26 Asset Turnover is 0.00 as of Dec. 2025. GuruFocus rates FRA:8NN with a GF Score™ of 26/100. The stock has 2 warning signs investors should review.

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Thor Medical ASA's Revenue for the six months ended in Dec. 2025 was €0.03 Mil. Thor Medical ASA's Total Assets for the quarter that ended in Dec. 2025 was €54.13 Mil. Therefore, Thor Medical ASA's Asset Turnover for the quarter that ended in Dec. 2025 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Thor Medical ASA's annualized ROE % for the quarter that ended in Dec. 2025 was -12.05%. It is also linked to ROA % through Du Pont Formula. Thor Medical ASA's annualized ROA % for the quarter that ended in Dec. 2025 was -8.83%.


Thor Medical ASA  (FRA:8NN) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Thor Medical ASA's annulized ROE % for the quarter that ended in Dec. 2025 is

ROE %**(Q: Dec. 2025 )
=Net Income/Total Stockholders Equity
=-4.782/39.6855
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-4.782 / 0.068)*(0.068 / 54.133)*(54.133/ 39.6855)
=Net Margin %*Asset Turnover*Equity Multiplier
=-7032.35 %*0.0013*1.364
=ROA %*Equity Multiplier
=-8.83 %*1.364
=-12.05 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Thor Medical ASA's annulized ROA % for the quarter that ended in Dec. 2025 is

ROA %(Q: Dec. 2025 )
=Net Income/Total Assets
=-4.782/54.133
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-4.782 / 0.068)*(0.068 / 54.133)
=Net Margin %*Asset Turnover
=-7032.35 %*0.0013
=-8.83 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Thor Medical ASA Asset Turnover Related Terms


Thor Medical ASA Asset Turnover Historical Data

* Premium members only.

The historical data trend for Thor Medical ASA's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Thor Medical ASA Asset Turnover Chart

Thor Medical ASA Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Thor Medical ASA Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

FRA:8NN vs VRTX, REGN, ALNY: Asset Turnover Comparison

For the Biotechnology subindustry, Thor Medical ASA's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Thor Medical ASA Asset Turnover vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Thor Medical ASA's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Thor Medical ASA's Asset Turnover falls into.


FRA:8NN
26GF Score
Thor Medical ASA FRA:8NN
Asset Turnover is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Thor Medical ASA Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Thor Medical ASA's Asset Turnover for the fiscal year that ended in Dec. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2025 )/( (Total Assets (A: Dec. 2024 )+Total Assets (A: Dec. 2025 ))/ count )
=0.037/( (35.269+59.878)/ 2 )
=0.037/47.5735
=0.00

Thor Medical ASA's Asset Turnover for the quarter that ended in Dec. 2025 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=0.034/( (48.388+59.878)/ 2 )
=0.034/54.133
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.

Frequently Asked Questions Learn more about Asset Turnover →
What does a Asset Turnover of 0.00 mean?
Thor Medical ASA (FRA:8NN) has a Asset Turnover of 0.00 as of Dec. 2025. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Thor Medical ASA and its competitors.
Is Thor Medical ASA's Asset Turnover too high?
Thor Medical ASA's current Asset Turnover is 0.00. Overall, Thor Medical ASA has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Thor Medical ASA's Asset Turnover compare to VRTX and REGN?
Thor Medical ASA's Asset Turnover of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Biotechnology company?
A good Asset Turnover depends on the Biotechnology industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Thor Medical ASA and its competitors. Thor Medical ASA's current Asset Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thor Medical ASA stock overvalued right now?
Thor Medical ASA (FRA:8NN) has a current Asset Turnover of 0.00. The current Asset Turnover is 0.00. Thor Medical ASA's overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For Thor Medical ASA (FRA:8NN), the current Asset Turnover is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Thor Medical ASA Business Description

Other Exchanges TRMED:Norway0R6Y:UK
Address Drammensveien 167, Oslo, NOR, 0277
Thor Medical ASA is a Norway-based biopharmaceutical company. The company is a producer and supplier of alpha-particle emitters for cancer therapy. The production process is based on separation of natural occurring radioactive decay products from thorium. The Company is utilizing alpha-emitters in radiotherapy and cancer treatments using Pb-212, which can be produced from naturally occurring isotope Thorium-232 and Lead-212. It uses a proprietary production process that does not involve irradiation or nuclear reactors to produce alpha-emitting materials. These materials are used by radiopharmaceutical companies in the development of cancer therapies.
26GF Score

Get the complete analysis for FRA:8NN

Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.37
Price